GlassScriptPhysician profile
Richard A Swift
NPI 1619979945
$4,491.76
in general payments reported to CMS, 2019-2025
29 companies · $927 in 2025
The $927 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $583 · 2021: $556 · 2022: $443 · 2023: $657 · 2024: $480 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,074.37 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,048.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.36 | 2019-2025 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Insmed, INC. | $329.81 | 2020-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $223.41 | 2021-2025 | |
| Mylan Specialty L.P. | $198.36 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $149.10 | 2020-2025 | Dupixent |
| Amgen INC. | $143.95 | 2022-2025 | Tezspire |
| Philips North America LLC | $117.86 | 2019-2025 | Vest Therapy Und |
| Verona Pharma, INC. | $87.55 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $77.71 | 2023-2025 | Wakix |
| Sunovion Pharmaceuticals INC. | $52.43 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $49.28 | 2019 | |
| Genentech USA, INC. | $40.61 | 2019 | |
| Viatris Specialty LLC | $39.38 | 2025 | Yupelri |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $34.76 | 2020 | |
| Grifols USA, LLC | $31.70 | 2022 | |
| Portola Pharmaceuticals, LLC | $30.68 | 2019 | |
| Shionogi INC | $25.85 | 2024 | Fetroja |
| Mallinckrodt Hospital Products INC. | $25.16 | 2021 | |
| Electromed, INC. | $24.54 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.94 | 2024 | Glassia |
| Vapotherm INC | $20.35 | 2021 | |
| Vifor Pharma, INC. | $19.45 | 2025 | Veltassa |
| Astellas Pharma US INC | $19.10 | 2019 | |
| Circassia INC. | $15.96 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.82 | 2020 | |
| United Therapeutics Corporation | $15.62 | 2025 | Tyvaso |
| Teva Pharmaceuticals USA, INC. | $11.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Swift listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.